Sylvain Perruche/LinkedIn
Apr 4, 2026, 08:36
Sylvain Perruche: Reactivating the Body Own Resolution Program in Inflammatory Disease
Sylvain Perruche, Founder and CEO of Med’Inn’Pharma, Co-Founder and Member of the Scientific Committee at Innovative Therapies Days, shared a post on LinkedIn:
“Inflammatory diseases have traditionally been treated by blocking the immune system.
Over the past decades, therapies have evolved:
- from broad immunosuppression
- to targeted cytokine inhibition
- to cell therapies
But the next frontier may be different.
Instead of suppressing inflammation, what if we could reactivate the body’s own resolution program?
At Med’Inn’Pharma, we are developing macrophage-derived secretome therapeutics designed to restore immune homeostasis and promote tissue repair.
A shift from blocking inflammation – resolving it.”
Stay updated with Hemostasis Today.
-
Oct 6, 2026, 22:43Alessandra Bosch: Pediatric GTH Opens with Regional Experts Convening on Pediatric Hemostasis and Thrombosis
-
Oct 6, 2026, 22:39Managing Thrombotic Risk in Pregnancy – How the Lab May Help – Sysmex Europe
-
Oct 6, 2026, 22:33Ahmet Davut Aksu: A Multi-Objective Approach to Enhance Fibrinolysis, Selectivity, and Inhibition Resistance
-
Oct 6, 2026, 22:29Muhammad Abubakar: New Study on Iron Biology to Be Presented at ASH 2026 and Published in Blood
-
Oct 6, 2026, 22:24David McIntosh: Calling On Decision-Makers to Prioritize Donors and Clinical Access During IPAW 2026
-
Oct 6, 2026, 22:21Zoltan Nagy: With All Eyes on Optogenetics Today, What Can It Do in Megakaryocytes and Platelets?
-
Oct 6, 2026, 22:13Khalid A. Fakhro: Sidra Medicine Hosts RAPID 2026 Advancing Diagnostics and Treatments for Inborn Errors of Immunity
-
Oct 6, 2026, 22:04Denis Oduor: Preparedness for Postpartum Haemorrhage Must Include Preparedness for Blood
-
Oct 6, 2026, 21:57Farhad Moradpour: Health Equity and Public Health – What Drives Anemia Disparities in Ethnic Minority Populations?